This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nesterova, M. Articles by Cho-Chung, Y. S. Search for Related Content PubMed PubMed Citation Articles by Nesterova, M. Articles by Cho-Chung, Y. S.

Compensatory Stabilization of RII_ß Protein, Cell Cycle Deregulation, and Growth Arrest in Colon and Prostate Carcinoma Cells by Antisense-directed Down-Regulation of Protein Kinase A RI Protein

Cellular Biochemistry Section, Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892-1750

The cyclic AMP-dependent protein kinase (PKA) exists in two isoforms, PKA-I (type I) and PKA-II (type II), that contain an identical catalytic (C) subunit but distinct regulatory (R) subunits, RI and RII, respectively. Increased expression of RI/PKA-I has been shown in human cancer cell lines, in primary tumors, in cells after transformation, and in cells upon stimulation of growth. We have shown previously that a single-injection RI antisense treatment results in a reduction in RI and PKA-I expression and sustained inhibition of human colon carcinoma growth in athymic mice (M. Nesterova and Y. S. Cho-Chung, Nat. Med., 1: 528–533, 1995). Growth inhibition accompanied reduction in RI/PKA-I expression and compensatory increases in RII_ß protein and PKA-II_ß, the RII_ß-containing holoenzyme. Here, we report that these in vivo findings are consistent with observations made in cancer cells in culture. We demonstrate that the antisense depletion of RI in cancer cells results in increased RII_ß protein without increasing the rate of RII_ß synthesis or RII_ß mRNA levels. Pulse-chase experiments revealed a 3–6-fold increase in the half-life of RII_ß protein in antisense-treated colon and prostate carcinoma cells with little or no change in the half-lives of RI, RII, and C proteins. Compensation by RII_ß stabilization may represent a novel biochemical adaptation mechanism of the cell in response to sequence-specific loss of RI expression, which leads to sustained down-regulation of PKA-I activity and inhibition of tumor growth.

This article has been cited by other articles:

				H. Wang, M. Li, W. Lin, W. Wang, Z. Zhang, E. R. Rayburn, J. Lu, D. Chen, X. Yue, F. Shen, et al. Extracellular Activity of Cyclic AMP-Dependent Protein Kinase as a Biomarker for Human Cancer Detection: Distribution Characteristics in a Normal Population and Cancer Patients Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 789 - 795. [Abstract] [Full Text] [PDF]

				M. V. Nesterova, N. R. Johnson, T. Stewart, S. Abrams, and Y. S. Cho-Chung CpG Immunomer DNA Enhances Antisense Protein Kinase A RI{alpha} Inhibition of Multidrug-Resistant Colon Carcinoma Growth in Nude Mice: Molecular Basis for Combinatorial Therapy Clin. Cancer Res., August 15, 2005; 11(16): 5950 - 5955. [Abstract] [Full Text] [PDF]

				E. Parrella, M. Gianni', V. Cecconi, E. Nigro, M. M. Barzago, A. Rambaldi, C. Rochette-Egly, M. Terao, and E. Garattini Phosphodiesterase IV Inhibition by Piclamilast Potentiates the Cytodifferentiating Action of Retinoids in Myeloid Leukemia Cells: CROSS-TALK BETWEEN THE cAMP AND THE RETINOIC ACID SIGNALING PATHWAYS J. Biol. Chem., October 1, 2004; 279(40): 42026 - 42040. [Abstract] [Full Text] [PDF]

				Y. S. Cho and Y. S. Cho-Chung Antisense Protein Kinase A RI{alpha} Acts Synergistically with Hydroxycamptothecin to Inhibit Growth and Induce Apoptosis in Human Cancer Cells: Molecular Basis for Combinatorial Therapy Clin. Cancer Res., March 1, 2003; 9(3): 1171 - 1178. [Abstract] [Full Text] [PDF]

				Y. S. Cho, M.-K. Kim, L. Tan, R. Srivastava, S. Agrawal, and Y. S. Cho-Chung Protein Kinase A RI{alpha} Antisense Inhibition of PC3M Prostate Cancer Cell Growth: Bcl-2 Hyperphosphorylation, Bax Up-Regulation, and Bad-Hypophosphorylation Clin. Cancer Res., February 1, 2002; 8(2): 607 - 614. [Abstract] [Full Text] [PDF]